News and Announcements
Novogen, The Future of Cancer Therapy, Releases Jun 2017 Newsletter
- Published June 07, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Novogen (ASX: NRT) is an Australian oncology-focused biotechnology company that is pleased to present the company’s June 2017 Newsletter.
KEY TAKEAWAYS:
- In April, Novogen planned phase II clinical trial in relation to the most common and aggressive form of primary brain cancer. Novogen plans to focus the study on the almost two-thirds of patients.
- Approximately 200 patients will be recruited, and the company aims to start the study in the second half of calendar 2017.
- The study will be a randomised controlled trial and, if it is successful, it may offer an opportunity to approach FDA, the US regulatory agency, to discuss accelerated approval without waiting for a full phase III study.
- Phase I study of Cantrixil in ovarian cancer is progressing well. Five of the six participating hospitals are now open to recruitment. The timing of initial data is difficult to predict, because the design entails increasing doses until patients start to experience side effects, and this cannot be accurately predicted in advance.
- Novogen’s decision during April to terminate the development of Anisina, the lead program from the company’s anti-tropomyosin research. Despite the great work that has been done with Anisina, the emerging data did not, in our view, make it a promising candidate to take forward into human trials.
- In closing, the Novogen team remains tightly focused on delivering its programs.
Company Updates
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
The Best of Both Worlds: How Omnique Fund is Rewiring Real World Assets via Tokenisation
For decades, the playbook for Australia’s wholesale investors has remained relatively unchanged: pick between the slow-moving, illiquid reliability of tangible assets like property and gold, or chase the frictionless, high-velocity liquidity of public equity and digital markets. But as macroeconomic volatility spikes and a structural housing deficit reshapes private debt demand, sophisticated investors are demanding […]
Everything is now competing for the same dollar
Key takeaways As recently as 2022, Germany and Japan could borrow for 30 years at close to zero. That world is gone, and AI is now bidding for what is left. Over the past fortnight, I listened to founders, operators and allocators describe where their industries are heading. They covered four very different frontiers. Each […]
Backed By Leading Investment Groups and Family Offices
